Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28235216 | 0.74 | POLB (0.37) | POLBL3MBTL1RAB9ASPHK1KMT2A | |
| SCHEMBL28015756 | 0.71 | POLB (0.43) | POLBL3MBTL1RAB9ASPHK1SPHK2 | |
| SCHEMBL15521588 | 0.70 | POLB (0.41) | POLBL3MBTL1SPHK1MEN1KMT2A | |
| SCHEMBL25361796 | 0.70 | POLB (0.41) | POLBL3MBTL1SPHK1MEN1KMT2A | |
| SCHEMBL3360692 | 0.70 | RAB9A (0.64) | POLBL3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL6960540 | 0.69 | SPHK1 (0.46) | POLBL3MBTL1SPHK1GBA1SPHK2 | |
| SCHEMBL13995203 | 0.69 | SPHK1 (0.46) | POLBL3MBTL1SPHK1GBA1SPHK2 | |
| SCHEMBL12311420 | 0.69 | L3MBTL1 (0.41) | POLBL3MBTL1RAB9A | |
| SCHEMBL12311416 | 0.69 | L3MBTL1 (0.41) | POLBL3MBTL1RAB9A | |
| SCHEMBL19903704 | 0.68 | SPHK1 (0.43) | POLBL3MBTL1SPHK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | POLB 1539/4885L3MBTL1 590/4885RAB9A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.